Home/Pipeline/V3402

V3402

Influenza

Phase 3Active, Ongoing

Key Facts

Indication

Influenza

Phase

Phase 3

Status

Active, Ongoing

Company

Merck

About Merck

Merck & Co. is a research-intensive biopharmaceutical giant with a foundational mission to put medicine before profits, driving global health impact. Its strategic focus is on high-growth therapeutic areas, most notably oncology led by blockbuster KEYTRUDA, complemented by a robust vaccine portfolio and promising pipeline. The company leverages a multi-modal technology platform and significant financial strength to sustain innovation, navigate patent cliffs, and pursue strategic business development to fuel long-term growth.

View full company profile

Therapeutic Areas

Oncology Vaccines Immunology Cardiometabolic Infectious Diseases Neuroscience

Other Influenza Drugs

Drug	Company	Phase	Status
PanCytoVir™ (oral probenecid)	TrippBio	IND Submitted	Active
Influenza Antibodies	new/era/mabs	Research/Pre-clinical	Active
Influenza Countermeasure Program	DynPort Vaccines	Not Specified	Active
Influenza Vaccine	Medigen	Preclinical	Active
Nasal Influenza Vaccine	Abera Bioscience	Pre-clinical	Active
Zapnometinib (ATR-002)	Atriva Therapeutics	Phase 2	Active
EV25	Eradivir	Pre-clinical	Active
Not Specified	New Amsterdam Sciences	Pre-clinical	Active
Influenza Program	Arisan Therapeutics	Preclinical	Active
Universal Influenza Vaccine	Orlance	Pre-IND	Active
Enhanced Seasonal Influenza Vaccine	Orlance	Research	Active
Baloxavir marboxil (Xofluza®)	Shionogi	Marketed	Commercial (via Roche)